Successful use of rituximab for cutaneous vasculitis

Archives of Dermatology

Volumn 142, Issue 11, 2006, Pages 1407-1410

  Chung, Lorinda ^a   Funke, Alisa A ^b   Chakravarty, Eliza F ^a   Callen, Jeffrey P ^b   Fiorentino, David F ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Louisville School of Medicine   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; AZATHIOPRINE; CHLORMETHINE; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DEXAMETHASONE; DOXEPIN; ERYTHROPOIETIN; ETANERCEPT; HYDROXYZINE; IMMUNOGLOBULIN; LISINOPRIL; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE;

ADULT; ANAMNESIS; ANGIONEUROTIC EDEMA; ARTICLE; BURNING SENSATION; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DOSE RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; LABORATORY TEST; LEUKOCYTOCLASTIC VASCULITIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TREATMENT RESPONSE;

ABDOMEN; ADULT; ANTIBODIES, MONOCLONAL; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOREARM; HUMANS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; KIDNEY TRANSPLANTATION; LEG; LYMPHOMA, NON-HODGKIN; SKIN DISEASES, VASCULAR;

EID: 33751250506     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.11.1407     Document Type: Article

References (24)

1. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med. 2005;257:540-548.
2. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:262-268.
3. Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999;26(suppl 14):66-73.
4. Lamprecht P, Lerin-Lozano C, Merz H, et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis. 2003;62:1230-1233.
5. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood. 2003;101:3818-3826.
6. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003;101:3827-3834.
7. Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of rituximab. Anticancer Drugs. 2002;13(suppl 2):S3-S10.
8. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46:2673-2677.
9. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580-2589.
10. Aggarwal A, Grewal R, Green RJ, et al. Rituximab for autoimmune haemophilia: a proposed treatment algorithm. Haemophilia. 2005;11:13-19.
11. Braendstrup P, Bjerrum OW, Nielsen OJ, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol. 2005;78:275-280.
12. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952-957.
13. Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003;101:3857-3861.
14. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572-2581.
15. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002;61:883-888.
16. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52:601-607.
17. Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol. 2005;153:620-625.
18. Dereure O, Navarro R, Rossi JF, Guilhou JJ. Rituximab-induced vasculitis. Dermatology. 2001;203:83-84.
19. Adler M, Soliotis F, Thakrar S, Stratton R. Use of rituximab in two unusual antibody-mediated autoimmune disorders. J R Soc Med. 2005;98:271-272.
20. Saigal K, Valencia IC, Cohen J, Kerdel FA. Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab. J Am Acad Dermatol. 2003;49(suppl):S283-S285.
21. Ghobrial IM, Uslan DZ, Call TG, Witzig TE, Gertz MA. Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenstrom macroglobulinemia does not indicate failure of response. Am J Hematol. 2004;77:329-330.
22. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med. 2005;173:180-187.
23. Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol. 2005;34:229-232.
24. Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64:913-920.